文献速递药物不良反应与药物警戒

依维莫司相关骨髓水肿一例报告

Bone marrow edema associated with everolimus.
PubMed 文献 · Am J Health Syst Pharm · 2018-01-01

一例62岁转移性胰腺神经内分泌肿瘤女性患者,在开始依维莫司治疗约4个月后出现双下肢水肿和疼痛,经磁共振成像诊断为骨髓水肿及跟骨压缩性骨折。经临床药师分析排除其他原因后停用依维莫司,症状在10天内完全缓解,Naranjo量表评分为6分,提示为很可能的不良反应。

要点

  • 使用依维莫司期间出现下肢水肿和疼痛需警惕骨髓水肿可能。
  • 磁共振成像有助于确诊骨髓水肿及压缩性骨折。
  • 疑似依维莫司相关骨髓水肿时应考虑停药并评估不良反应关联性。

核心结论

  • 依维莫司治疗转移性胰腺神经内分泌肿瘤期间可能发生骨髓水肿及跟骨压缩性骨折,停药后症状完全缓解。

研究设计与样本

  • 单例病例报告:62岁女性转移性胰腺神经内分泌肿瘤患者,接受依维莫司治疗后出现双下肢水肿和疼痛。

主要发现

  • 开始依维莫司约4个月后出现双下肢水肿和疼痛,磁共振成像诊断为骨髓水肿和跟骨压缩性骨折。
  • 停用依维莫司后10天内症状完全恢复;Naranjo不良反应概率量表评分为6分,提示很可能为依维莫司所致。
  • hypothesized mechanism includes marrow edema and hyperemia from reduced intraosseous perfusion, previously reported with mTOR inhibitor use.

关键数值与推荐

  • Naranjo不良反应概率量表评分为6分,对应「很可能」的不良反应关联性。

临床怎么用

  • 临床药师应参与疑似依维莫司不良反应的评估,排除其他病因后及时建议停药。

局限性

  • 单例病例报告,不能确立因果关系或估计发生率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The case of a patient who experienced bone marrow edema and pain in both feet and a compression fracture of one heel bone after several months of everolimus use is reported. SUMMARY: A 62-year-old woman with a grade 1 metastatic pancreatic neuroendocrine tumor (pNET) developed bilateral lower extremity edema and pain approximately 4 months after initiation of treatment with everolimus, an inhibitor of mammalian (or mechanistic) target of rapamycin (mTOR). The patient was referred for orthopedic evaluation, which resulted in diagnosis of bone marrow edema and a compression fracture of the calcaneus on the basis of magnetic resonance imaging results. The case was discussed with a clinical pharmacist, and after an in-depth analysis to rule out potential alternative causes for the patient's edema and pain, everolimus was discontinued. The patient had a full recovery from the presenting symptoms within 10 days of discontinuation of everolimus. Analysis of this case using the adverse drug reaction probability scale of Naranjo et al. yielded a score of 6, indicating a probable adverse reaction to everolimus. A hypothesized mechanism for everolimus-induced bone pain includes marrow edema and hyperemia from reduced intraosseous perfusion, which have been previously reported in association with mTOR inhibitor use. CONCLUSION: Bone marrow edema developed and a fracture occurred in a patient taking everolimus for a metastatic pNET, with complete resolution of lower extremity swelling and pain within 2 weeks of everolimus discontinuation.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. McDevitt RL, Quinlan C, Hersberger K, et al. Bone marrow edema associated with everolimus. Am J Health Syst Pharm. 2018. PMID: 29273609. doi:10.2146/ajhp170269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。